CJ Bioscience Balance Sheet Health
Financial Health criteria checks 5/6
CJ Bioscience has a total shareholder equity of ₩56.1B and total debt of ₩5.1B, which brings its debt-to-equity ratio to 9.1%. Its total assets and total liabilities are ₩75.8B and ₩19.7B respectively.
Key information
9.1%
Debt to equity ratio
₩5.11b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩49.75b |
| Equity | ₩56.11b |
| Total liabilities | ₩19.67b |
| Total assets | ₩75.78b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A311690's short term assets (₩51.7B) exceed its short term liabilities (₩14.6B).
Long Term Liabilities: A311690's short term assets (₩51.7B) exceed its long term liabilities (₩5.0B).
Debt to Equity History and Analysis
Debt Level: A311690 has more cash than its total debt.
Reducing Debt: A311690's debt to equity ratio has increased from 4% to 9.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A311690 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A311690 has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 37.4% each year.